kresmion.
Pull a receipt

Atara Biotherapeutics, Inc. (ATRA)

Sector
Healthcare
Industry
Biotechnology
Last price
$7.87
As of

Kresmion compiles this page from ATRA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Atara Biotherapeutics, Inc. (ATRA): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-12.

As of . Source: SEC EDGAR filings for ATRA. Method and limitations.

COMPANY DOSSIER

See the full ATRA dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for ATRA on one page. Preview it with sample data, then open it live with a free account.

Preview the ATRA dossier

Active events for ATRA

FREE, NO ACCOUNT

Every event on ATRA, as it fires

You are seeing 5 of 8 events recorded on ATRA since 2026-05-31.

The five above landed across 3 days. The other 3 were recorded on those same days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

ATRA positions held by the managers we follow (2026Q2)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
Point72 Asset Management, L.P. FundCUSIP 046513206 · 2026Q2$7.9M0.01%
MILLENNIUM MANAGEMENT LLC FundCUSIP 046513206 · 2026Q2$146K0.00%
CITADEL ADVISORS LLC FundCUSIP 046513206 · 2026Q2$117K0.00%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ATRA

Going concern statement

ATRA's 10-Q filed Aug 12, 2026 states:

Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.

Read the 10-Q on SEC EDGAR Every company with a going concern statement

More data on ATRA

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in ATRA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ATRA in the last 180 days.

Upstream: SEC EDGAR filings for ATRA

Kresmion, "Atara Biotherapeutics, Inc. (ATRA) institutional holdings and SEC filings", data as of 2026-08-16, https://kresmion.com/research/ATRA. Upstream data: SEC EDGAR filings for ATRA.

Link to this data (HTML):

<a href="https://kresmion.com/research/ATRA">Atara Biotherapeutics, Inc. (ATRA) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow ATRA on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ATRA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the ATRA dossier
Share

The ATRA intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.